Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome

Blood

Volumn 98, Issue 4, 2001, Pages 979-987

  Stetler Stevenson, Maryalice ^a,b,c   Arthur, Diane C ^a,b,c   Jabbour, Nicholas ^a,b,c   Xie, Xiu Y ^a,b,c   Molldrem, Jeff ^a,b,c   Barrett, A John ^a,b,c   Venzon, David ^a,b,c   Rick, Margaret E ^a,b,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; APLASTIC ANEMIA; ARTICLE; CYTOGENETICS; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC CELL; HUMAN; IMMUNOPHENOTYPING; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REMISSION; SENSITIVITY AND SPECIFICITY;

EID: 0035883086     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.4.979     Document Type: Article

References (17)

1. Tricot GJ. Minimal diagnostic criteria for the myelodysplastic syndrome in clinical practice. Leuk Res. 1992;16:5-9.
2. Ost A, Reizenstein P. Minimal diagnostic criteria for the myelodysplastic syndrome. Leuk Res. 1992;16:9-11.
3. Nand S, Godwin JE. Hypoplastic myelodysplastic syndrome. Cancer. 1988;62:958-964.
4. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189-199.
5. Kampmeier P, Anastasi J, Vardiman JW. Issues in the pathology of the myelodysplastic syndromes. Hematol Oncol Clin North Am. 1992;6:501-522.
6. Fohlmeister I, Fischer R, Modder B, et al. Aplastic anemia and the hypocellular myelodysplastic syndrome: histomorphological, diagnostic and prognostic features. J Clin Pathol. 1985;38:1218-1224.
7. Barrett J, Saunthararajah Y, Molldrem J. Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin Hematol. 2000;37:15-29.
8. Mecucci C, Van den Berghe H. Cytogenetics. Hematol Oncol Clin North Am. 1992;6:523-541.
9. Yunis JJ. High resolution chromosome analysis in the prognosis and clinical evolution of de novo myelodysplasia. Haematologica. 1987;72:34-36.
10. Geddes AD, Bowen DT, Jacobs A. Clonal karyotype abnormalities and clinical progress in the myelodysplastic syndrome. Br J Haematol. 1990;76:194-202.
11. Kuiper-Kramer PA, Huisman CM, Van der Molen-Sinke J, Abbes A, Van Eijk HG. The expression of transferrin receptors on erythroblasts in anemia of chronic disease, myelodysplastic syndromes and iron deficiency. Acta Haematol. 1997;97:127-131.
12. Bowen KL, Davis BH. Abnormal patterns of expression of CD16 (FcR-III) and CD11 b (CRIII) antigens by developing neutrophils in the bone marrow of patients with myelodysplastic syndrome. Lab Hematol. 1997;3:292-298.
13. Kanter-Lewensohn L, Hellstrom-Lindberg E, Kock Y, Elmhorn-Rosenborg A, Ost A. Analysis of CD34 positive cells in bone marrow from patients with myelodysplastic syndrome and acute myeloid leukemia and in normal individuals: a comparison between FACS analysis and immunohistochemistry. Eur J Haematol. 1996;56:124-129.
14. Hensen IM, Hokland P. The proliferative activity of myelopoiesis in myelodysplasia evaluated by multiparameter flow cytometry. Br J Haematol. 1994;87:477-482.
15. Fukushima PI, Nguyen PKT, O'Grady P, Stetler-Stevenson M. Flow cytometric analysis of kappa and lambda light chain expression in evaluation of specimens for B-cell neoplasia. Cytometry. 1996;26:243-252.
16. Qiao X, Loudovaris M, Unverzagt K, et al. Immunocytochemistry and flow cytometric evaluation of human megakaryocytes in fresh samples and cultures of CD34+ cells. Cytometry. 1996;23:250-259.
17. Aul C, Germing U, Gattermann N, Minning H. Increasing incidence of myelodysplastic syndromes: real or fictitious? Leuk Res. 1998;22:93-100.